Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Upstream Bio (UPB) Liabilities and Shareholders Equity (2023 - 2025)

Historic Liabilities and Shareholders Equity for Upstream Bio (UPB) over the last 3 years, with Q3 2025 value amounting to $391.2 million.

  • Upstream Bio's Liabilities and Shareholders Equity rose 6811.13% to $391.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 billion, marking a year-over-year increase of 40003.26%. This contributed to the annual value of $481.7 million for FY2024, which is 31103.01% up from last year.
  • Latest data reveals that Upstream Bio reported Liabilities and Shareholders Equity of $391.2 million as of Q3 2025, which was up 6811.13% from $420.5 million recorded in Q2 2025.
  • Over the past 5 years, Upstream Bio's Liabilities and Shareholders Equity peaked at $481.7 million during Q4 2024, and registered a low of $117.2 million during Q4 2023.
  • Moreover, its 3-year median value for Liabilities and Shareholders Equity was $405.9 million (2025), whereas its average is $349.9 million.
  • In the last 5 years, Upstream Bio's Liabilities and Shareholders Equity soared by 31103.01% in 2024 and then surged by 6811.13% in 2025.
  • Over the past 3 years, Upstream Bio's Liabilities and Shareholders Equity (Quarter) stood at $117.2 million in 2023, then surged by 311.03% to $481.7 million in 2024, then fell by 18.79% to $391.2 million in 2025.
  • Its last three reported values are $391.2 million in Q3 2025, $420.5 million for Q2 2025, and $456.2 million during Q1 2025.